|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The metabolomics data were tested for correlation with glioma grade (high vs low), glioblastoma (GBM) versus malignant gliomas, and IDH mutation status.
|
26967252 |
2016 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma.
|
31371189 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant.
|
30710203 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, five tumors were IDH wild-type (IDHwt) and had chromosome seven gains, chromosome 10 losses, and homozygous 9p deletions (CDKN2A), alterations typical of IDHwt (primary) GBM.
|
26757882 |
2016 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among the WHO grade II and III gliomas, IDH1 mutations were significantly associated with preoperative seizures, but no significant relationship between IDH mutations and preoperative seizures was found with glioblastoma multiforme.
|
27406953 |
2016 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The metabolic genes isocitrate dehydrogenase 1 (IDH1) and IDH2 are commonly mutated in low-grade glioma and in a subset of glioblastoma.
|
28980701 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Most lower-grade gliomas without an IDH mutation were molecularly and clinically similar to glioblastoma.
|
26061751 |
2015 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The discovery of somatic mutations in the isocitrate dehydrogenase (IDH) enzymes through a genome-wide mutational analysis in glioblastoma represents a milestone event in cancer biology.
|
20972461 |
2010 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
While consensus has not been reached on the precise nature and means to sub-classify GBM, it is clear that IDH-mutant GBMs are clearly distinct from GBMs without IDH1/2 mutation with respect to molecular and clinical features, including prognosis.
|
25943888 |
2015 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
From 578 total gliomas tested, 88 were IDH-mutant DA/AA/GBMs and 11 IDH-mutant tumors were in persons age 55 and older.
|
28110298 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
At present, GBMs are divided in primary and secondary on the basis of the mutational status of the isocitrate dehydrogenase (IDH) genes.
|
30987226 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We also identified protein signatures for GBMs with genetic alterations (IDH mutation, p53 mutation, EGFR amplification or mutation, CDKN2A/CDKN2B deletion, and PTEN mutation) that occur at high frequency.
|
30401645 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in IDH genes are observed in over 70% of low-grade gliomas and some cases of glioblastoma.
|
26485760 |
2015 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
EGFR amplification (EGFRamp), the combination of gain of chromosome 7 and loss of chromosome 10 (7+/10-), and TERT promoter mutation (pTERTmut) are alterations frequently observed in adult IDH-wild-type (IDHwt) glioblastoma (GBM).
|
30187121 |
2018 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Characterization of diverse immune responses will facilitate patient stratification and improve personalized immunotherapy in the future.<b>Significance:</b> This study utilizes a computational approach to characterize the immune environments in glioblastoma and shows that glioblastoma immune microenvironments can be classified into three major subgroups, which are linked to typical glioblastoma alterations such as IDH mutation, NF1 inactivation, and CDK4-MARCH9 locus amplification.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/19/5574/F1.large.jpg <i></i>.
|
29921698 |
2018 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Both of MGMT promoter methylation and IDH mutation had a cumulative effect on the OS of GBM patients.
|
27764705 |
2016 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We excluded glioblastoma-like tumors (7a10d subgroup) and derived a gene expression signature distinguishing histologically classified oligodendrogliomas with concurrent 1p/19q co-deletion and IDH mutation (1p/19q subgroup) from those with predominant IDH mutation alone (IDHme subgroup).
|
29631562 |
2018 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We analyzed The Cancer Genome Atlas dataset (TCGA) and identified a small group of IDH-mutant, WHO grade II-III astrocytomas (n = 14) with an unexpectedly poor prognosis characterized by a rapid progression to glioblastoma and death within 3 years of the initial diagnosis.
|
29741737 |
2018 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
One hundred twenty-six tumors could be classified: 20 as type II (IDH mutation [mut], "astrocytoma"), 49 as type I (1p/19q codeletion, "oligodendroglioma"), 55 as type III (7+/10q- or TERTmut and 1p/19q intact, "glioblastoma"), and 2 as childhood glioblastoma (H3F3Amut), leaving 7 unclassified (total 91% classified).
|
26354927 |
2016 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic astrocytoma, IDH-wildtype (AA-IDHwt) was the common molecular subgroup (52.8%), followed by diffuse astrocytoma, IDH-wildtype (DA-IDHwt) and AA, IDH-mutant (AA-IDHmt) (each 16.9%), DA-IDHmt (7.9%), glioblastoma (GBM)-IDHwt (3.3%) and GBM-IDHmt (2.2%).
|
31435963 |
2020 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.
|
26158269 |
2015 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, cell lines of IDH-wildtype GBM from primary cultures were obtained, and the role of SOCS1 and SOCS3 in the radiotherapy response was analysed.
|
30811476 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) is a major oncogenic driver in glioblastoma (GBM) without mutations in the isocitrate dehydrogenase gene (IDH-wildtype).
|
28765916 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
By direct genomic DNA sequencing, we analyzed exon 4 of the IDH1 and IDH2 genes that harbored the mutation hot spots codon 132 and 172 of the two genes in glioblastoma, respectively, in 12 thyroid cancer cell lines, 20 FTC, and 18 ATC tumor samples.
|
20171178 |
2010 |